A brain-computer interface company is preparing to begin human trials of an implant designed to treat depression and other mental health conditions.

Motif Neurotech has announced plans to test its brain implant technology in human subjects, marking a shift in the brain-computer interface field toward mental health applications. The company's approach differs from many competitors in the space, which have primarily focused on developing devices to help paralyzed individuals communicate or control external devices.

The planned trial represents part of a growing trend of companies exploring how brain implant technology might address psychiatric conditions. Brain-computer interfaces have shown promise in various medical applications, with some devices already approved for treating conditions like epilepsy and Parkinson's disease.

Details about the specific design of Motif Neurotech's device, the timeline for human trials, or regulatory approvals required have not been disclosed. The company has not provided information about how many patients would participate in initial testing or the specific mechanisms by which the implant would address depression symptoms.